Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas

Lung Cancer Immunotherapy

“…Dendritic cells have recently been investigated as a delivery mechanism for tumor-associated antigens. Both whole cell 42 and peptide 43 strategies have been reported. In one study, 18 patients with metastatic gastrointestinal or lung cancer and HLA-A24 were treated with autologous dendritic cells pulsed with CEA-derived peptide.…”

Hsp70-Like Protein 1 Fusion Protein Enhances Induction of Carcinoembryonic Antigen–Specific CD8+ CTL Response by Dendritic Cell Vaccine

“…The high expression makes it an attractive tumorassociated antigen for immunotherapeutic purposes (14). CEA as a target antigen of tumor therapy has been extensively evaluated in murine models and human by means of vaccinating recombinant CEA proteins (15), recombinant viruses carrying the CEA gene (16), CEA anti-idiotype antibodies (17), dendritic cells transfected with CEA RNA (18), or dendritic cells pulsed with agonist epitopes of CEA (14,(19)(20)(21). Although CEA is a selfantigen with a tendency to be immunologically tolerant, a HLA-A2.1-restricted CTL epitope peptide of CEA, CAP-1 (CEA [605][606][607][608][609][610][611][612][613] , YLSGANLNL), is a target for T cell lines derived from HLA-A2.1-positive patients with CEA-expressing malignancies (14,21).…”

“…Although CEA is a selfantigen with a tendency to be immunologically tolerant, a HLA-A2.1-restricted CTL epitope peptide of CEA, CAP-1 (CEA [605][606][607][608][609][610][611][612][613] , YLSGANLNL), is a target for T cell lines derived from HLA-A2.1-positive patients with CEA-expressing malignancies (14,21). Among vaccine approaches, dendritic cell-based active immunotherapy for CEA-positive human carcinomas is quite promising (18)(19)(20)(21). To further improve therapeutic efficacy of dendritic cellbased vaccines, some adjuvants have been used in combinations (22,23).…”

Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: Possible application for cancer immunotherapy

“…As a result, consistent with a previous report (41), these generated DCs were phenotypically and functionally equivalent to DCs generated from control monocytes. In fact, we have demonstrated that peptide-pulsed DCs generated in this manner could elicit optimal cytotoxic T-cell responses in some patients in a clinical study for cancer immunotherapy on patients bearing CEA-expressing solid cancer (42). On the other hand, we also previously demonstrated that a substantial number of CD34 + cells were mobilized in the peripheral blood and thus proposed the potential use of these G-CSF-mobilized CD34 + cells as a cell source for the expansion of pDCs in vitro (40).…”